Hydroxyurea therapy in children severely affected with sickle cell disease

被引:141
|
作者
Scott, JP
Hillery, CA
Brown, ER
Misiewicz, V
Labotka, RJ
机构
[1] CHILDRENS HOSP WISCONSIN, WISCONSIN SICKLE CELL DIS COMPREHENS CARE CTR, MILWAUKEE, WI 53226 USA
[2] MED COLL WISCONSIN, DEPT PEDIAT, MILWAUKEE, WI 53226 USA
[3] UNIV ILLINOIS, DEPT PEDIAT, CHICAGO, IL USA
来源
JOURNAL OF PEDIATRICS | 1996年 / 128卷 / 06期
关键词
D O I
10.1016/S0022-3476(96)70335-9
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Hypothesis: The major clinical manifestations of sickle cell disease (SCD) are hemolytic anemia, predisposition to infection, and recurrent vaso-occlusive episodes resulting in pain, organ dysfunction, or both. There has been no satisfactory treatment for children with recurrent severe painful episodes caused by SCD. Hydroxyurea is an antimetabolite drug shown in adults with SCD to increase fetal hemoglobin levels and reduce the symptoms of SCD. We hypothesized that hydroxyurea therapy in children with severe (defined as greater than or equal to 3 vaso-occlusive events per year) SCD could improve hematologic parameters and reduce vaso-occlusive events. Objective: To assess the safety and efficacy of hydroxyurea for the treatment of severe SCD in children. Study design: After obtaining informed consent, we initiated hydroxyurea therapy at a dosage of 10 to 20 mg/kg per day in 15 patients with severe SCD (hemoglobin SS, hemoglobin SS-alpha thalassemia, or hemoglobin S-beta(0)-thalassemia). Doses were escalated as tolerated. Patients were monitored with bimonthly physical examinations and monthly laboratory measures. To assess the impact of hydroxyurea on clinical symptoms, we recorded the number of inpatient days for each patient during the period of treatment and compared it with the number of inpatient days for the 12- to 24-month period before institution of hydroxyurea therapy, using the subject as his or her own control subject. Results: Thirteen patients received hydroxyurea for a median of 24 months (range, 6 to 39 months). The mean dose of hydroxyurea was 21.4 +/- 5.2 mg/kg. Treatment with hydroxyurea induced statistically significant increases in the total hemoglobin concentration, mean corpuscular volume, and percentage of hemoglobin F, and a decrease in the serum concentration of bilirubin. Toxic effects included three episodes of a reversible myelotoxic reaction, two of which required transfusion of packed erythrocytes. For the entire group, hospitalization decreased from a prehydroxyurea median of 3.9 +/- 2.0 days per month to 1.1 +/- 2.1 days per month of therapy (p = 0.09). For those subjects (n = 10) completing at least 1 year of treatment, the decrease in hospitalization from 4.1 +/- 2.2 to 1.0 +/- 1.7 days per month was significant (p = 0.03). Conclusions: In this pilot trial, hydroxyurea treatment of severe SCD in children was associated with improved hematologic parameters, acceptable toxic effects, and a trend to reduced hospitalization. Hydroxyurea appears to be a safe and potentially effective agent for the treatment of severe SCD in children. A prospective, controlled trial to investigate the efficacy of hydroxyurea in children is therefore warranted.
引用
收藏
页码:820 / 828
页数:9
相关论文
共 50 条
  • [31] Hydroxyurea therapy for children with sickle cell disease: Describing how caregivers make this decision
    Creary S.
    Zickmund S.
    Ross D.
    Krishnamurti L.
    Bogen D.L.
    [J]. BMC Research Notes, 8 (1)
  • [32] Three-year follow-up of hydroxyurea treatment in severely ill children with sickle cell disease
    deMontalembert, M
    Belloy, M
    Bernaudin, F
    Gouraud, F
    Capdeville, R
    Mardini, R
    Philippe, N
    Jais, JP
    Bardakdjian, J
    Ducrocq, R
    MaierRedelsperger, M
    Elion, J
    Labie, D
    Girot, R
    [J]. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 1997, 19 (04) : 313 - 318
  • [33] Hydroxyurea in sickle cell disease
    Schechter, AN
    Rodgers, GP
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (05): : 333 - 333
  • [34] Use of hydroxyurea in prevention of stroke in children with sickle cell disease
    Lefevre, Nicolas
    Dufour, Dominique
    Gulbis, Beatrice
    Le, Phu-Quoc
    Heijmans, Catherine
    Ferster, Alina
    [J]. BLOOD, 2008, 111 (02) : 963 - 964
  • [35] Effect of Hydroxyurea in Children With Sickle Cell Disease in Saudi Arabia
    Al Hawsawi, Zakaria Mohammed
    Turkistani, Waheed Ahmed
    [J]. JOURNAL OF TAIBAH UNIVERSITY MEDICAL SCIENCES, 2008, 3 (02): : 129 - 134
  • [36] EVALUATION OF HYDROXYUREA AND ERYTHROPOIETIN THERAPY IN SICKLE-CELL DISEASE
    GOLDBERG, MA
    BRUGNARA, C
    DOVER, GJ
    SCHAPIRA, L
    CHARACHE, S
    [J]. CLINICAL RESEARCH, 1990, 38 (02): : A300 - A300
  • [37] Pain Experiences in Children with Sickle Cell Disease in the Era of Hydroxyurea
    Kavanagh, Patricia
    Sprinz, Philippa G.
    Libernays, Evelyn
    Pavlus, Nicole
    Wang, C. Jason
    [J]. BLOOD, 2015, 126 (23)
  • [38] Population pharmacokinetics of hydroxyurea for children and adolescents with sickle cell disease
    Wiczling, Pawel
    Liem, Robert I.
    Panepinto, Julie A.
    Garg, Uttam
    Abdel-Rahman, Susan M.
    Kearns, Gregory L.
    Neville, Kathleen A.
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 54 (09): : 1016 - 1022
  • [39] Alterations in the Humoral Immunophenotype of Children with Sickle Cell Disease on Hydroxyurea
    Vistica-Sampino, Emily
    Chorzalska, Anna D.
    Bonal, Dennis M.
    Morgan, John
    Nguyen, Lisa
    Rodriguez, Anaelena
    Lulla, Rishi
    Dubielecka, Patrycja M.
    [J]. BLOOD, 2022, 140 : 2523 - 2525
  • [40] Is Hydroxyurea Treatment Changing the Life of Children with Sickle Cell Disease?
    Al Sabbah, Mohammed Ali
    Radaideh, Mahmoud
    Saleh, Shafeeka Mohammed
    Al-Doory, Sura Ahmed
    Abdalqader, Amal Mahmoud
    Mir, Fatima Farid
    Mohammed, Aya
    [J]. DUBAI MEDICAL JOURNAL, 2023, 6 (04): : 301 - 305